Zilucoplan: complete guide

Zilucoplan is a macrocyclic peptide complement C5 inhibitor approved by FDA as Zilbrysq in 2023. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved zilucoplan as Zilbrysq on October 17, 2023. It is a 15-amino-acid ring peptide with a molecular weight of 3,562 g/mol. In the RAISE trial, it improved a daily-living symptom score by 2.09 points more than placebo at week 12.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Zilbrysq on October 17, 2023.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited2 in this article · 2 across 1 article on Zilucoplan
Related productsBPC-157, TB-500 and thymic peptides

Zilucoplan is a synthetic macrocyclic peptide of 15 amino acids that blocks complement protein C5. FDA lists it among its novel drug approvals of 2023. This guide covers its structure, mechanism, FDA-labeled use, pivotal trial and label warnings. Sources were checked on November 17, 2026.

Quick answer: Zilucoplan is a prescription complement C5 inhibitor. Its label covers generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies. It carries a boxed warning for serious meningococcal infections and is available only through a REMS program.

Vitrapep does not sell zilucoplan; this page is a reference summary of published research and regulatory information.

What is zilucoplan?

The Zilbrysq label states: “Zilucoplan, a complement inhibitor, is a 15 amino-acid, synthetic macrocyclic peptide” (Zilbrysq label, 2026). Macrocyclic means the amino acid chain is closed into a large ring.

It counts as a peptide because its core is that 15-amino-acid ring. ChEBI text, quoted in PubChem, calls it “a homodetic cyclic peptide, a polyether and a macrocycle.” Homodetic means the ring is closed by peptide bonds only. The label’s chemical name also includes a palmitoyl (fatty acid) group and a polyethylene glycol-type chain attached to the ring. PubChem lists the formula as C172H278N24O55 and the molecular weight as 3,562 g/mol (PubChem CID 133083018). Our peptide primer and guide to peptide types explain the basics.

Drugs@FDA lists the original approval of Zilbrysq (NDA 216834) on October 17, 2023, to UCB (Drugs@FDA). FDA’s list of novel drug approvals for 2023 includes it (FDA, 2023 list).

Table 1

Zilucoplan: key facts

Fact Detail
Structure type Synthetic macrocyclic peptide of 15 amino acids, with lipid and PEG-type side groups
Class Complement C5 inhibitor
Molecular formula C172H278N24O55
Molecular weight 3,562 g/mol
First FDA approval October 17, 2023 (Zilbrysq, NDA 216834)
Brand names (US) Zilbrysq

How does zilucoplan work?

Complement is a set of blood proteins that helps the immune system destroy targets. Its last step assembles the terminal complement complex, C5b-9, which can punch holes in cell membranes.

Zilucoplan blocks that last step. The label states that it “binds to the complement protein C5 and inhibits its cleavage to C5a and C5b,” preventing C5b-9. The label adds that its exact effect in myasthenia gravis “is unknown.” It is presumed to reduce C5b-9 deposits at the neuromuscular junction, where nerve meets muscle. ChEBI lists its roles as “a complement component 5 inhibitor and an immunosuppressive agent.” Compare pegcetacoplan, a peptide drug that acts earlier, at C3.

What is zilucoplan approved for?

The Zilbrysq label lists one indication: “the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Generalized myasthenia gravis is an autoimmune disease that causes muscle weakness beyond the eye muscles. The label also lists a contraindication: Zilbrysq should not be started in patients with an unresolved serious Neisseria meningitidis infection.

What did the key trials show?

RAISE. This was a randomized, double-blind, placebo-controlled phase 3 human trial. It assigned 174 adults with AChR antibody-positive generalized myasthenia gravis: 86 to zilucoplan and 88 to placebo (NCT04115293).

The primary end point was the change in the Myasthenia Gravis Activities of Daily Living score at week 12. This scale rates 8 symptoms that affect daily function, from 0 to 24, with higher scores meaning more impairment. The label reports a mean change of −4.39 points with zilucoplan and −2.30 with placebo. The difference was −2.09 points (95% CI, −3.24 to −0.95; p=0.0004) (Howard et al., 2023).

The quantitative myasthenia gravis (QMG) score, a clinician-rated secondary end point, also favored zilucoplan by 2.94 points (p<0.001). The publication reports similar rates of serious adverse events and serious infections in the two groups. One patient died in each group, and neither death was judged related to the study drug.

RAISE-XT. This open-label extension enrolled 200 patients from the earlier controlled studies. At an interim cut-off, median exposure was 1.2 years. Patients who began on zilucoplan had a mean daily-living score change of −6.04 points from their original baseline at week 60. There was no control group at this stage. Worsening of myasthenia gravis (26%) and COVID-19 (25%) were the most common adverse events (Howard et al., 2024).

What side effects does the label list?

The Zilbrysq label has a boxed warning titled “Serious meningococcal infections.” It states that “life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors.” Because of this risk, Zilbrysq is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).

The label lists these as the most common adverse reactions in RAISE.

  • Local site reactions: 29% with zilucoplan and 16% with placebo.
  • Upper respiratory tract infections: 14% and 7%.
  • Diarrhea: 11% and 2%.

Other label warnings cover infections beyond meningococcal disease and “pancreatitis and other pancreatic conditions.”

What is zilucoplan’s regulatory status, and how is it used in research?

Zilucoplan is a prescription drug in the United States, sold as Zilbrysq by UCB. Distribution runs through a REMS because of the meningococcal infection risk. The current label was revised in January 2026. The RAISE registry record lists Ra Pharmaceuticals as lead sponsor; UCB is named as the organization on the record.

The research summarized here is clinical: a randomized human trial in generalized myasthenia gravis. We found no documented role for zilucoplan as a laboratory reagent in the sources we checked.

Frequently asked questions about zilucoplan

Is zilucoplan a peptide?

Yes. The label calls it a 15 amino-acid, synthetic macrocyclic peptide. Lipid and PEG-type groups are attached to the ring.

When was zilucoplan approved?

Drugs@FDA lists the original approval of Zilbrysq on October 17, 2023.

What does zilucoplan target?

Complement protein C5. Blocking C5 cleavage prevents the terminal complement complex that damages the nerve-muscle junction in myasthenia gravis.

Who is zilucoplan approved for?

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

Does zilucoplan have a boxed warning?

Yes. It warns of serious meningococcal infections, and the drug is available only through a REMS program.

What to know now

  • Structure: 15-amino-acid synthetic macrocyclic peptide; 3,562 g/mol.
  • Approval: Zilbrysq, October 17, 2023; prescription only.
  • Mechanism: binds C5 and blocks its cleavage into C5a and C5b.
  • Evidence: daily-living score improved 2.09 points more than placebo at week 12 in RAISE.
  • Label: AChR antibody-positive generalized myasthenia gravis in adults.
  • Safety: boxed warning for meningococcal infections; REMS program.

What we’re watching

Final results of the RAISE-XT extension. ClinicalTrials.gov lists it as completed, with primary completion on July 31, 2026 (NCT04225871). Further Zilbrysq label revisions on DailyMed. Related guides: pegcetacoplan, cyclosporine and ziconotide.

More for immune system

All 24 compounds for immune system

Sources: UCB 2026, ZILBRYSQ (zilucoplan) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 216834 (ZILBRYSQ) . Retrieved November 17, Drugs@FDA: NDA 216834 (ZILBRYSQ); National Center for Biotechnology Information 2026, PubChem compound summary for CID 133083018, zilucoplan; Howard 2023, The Lancet Neurology, 22; Howard 2024, Therapeutic Advances in Neurological Disorders, 17; UCB Biopharma SRL 2020, Open-label extension of zilucoplan in subjects with generalized myasthenia gravis; U.S. Food and Drug Administration 2026, Novel drug approvals for 2023; Ra Pharmaceuticals 2019. All 8 citations

Back to the research library

References

  1. UCB, Inc. (2026). ZILBRYSQ (zilucoplan) prescribing information (revised 1/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f1d53d6-e495-4a3a-8bb9-680a15d25034
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 216834 (ZILBRYSQ). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216834
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 133083018, zilucoplan. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/133083018
  4. Howard, J. F., Jr., et al. (2023). Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Neurology, 22(5), 395–406. https://doi.org/10.1016/S1474-4422(23)00080-7
  5. Howard, J. F., Jr., et al. (2024). Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: Interim analysis of the RAISE-XT open-label extension study. Therapeutic Advances in Neurological Disorders, 17, 17562864241243186. https://doi.org/10.1177/17562864241243186
  6. UCB Biopharma SRL. (2020). Open-label extension of zilucoplan in subjects with generalized myasthenia gravis (RAISE-XT; ClinicalTrials.gov ID NCT04225871). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04225871
  7. U.S. Food and Drug Administration. (2026). Novel drug approvals for 2023. Retrieved November 17, 2026, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
  8. Ra Pharmaceuticals. (2019). Safety, tolerability, and efficacy of zilucoplan in subjects with generalized myasthenia gravis (RAISE; ClinicalTrials.gov ID NCT04115293). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04115293